Noura Atef A Ebrahim, Moamen O Othman, Neveen S Tahoun, Rasha A Salama, Aya Arafat, Nancy H Amin
{"title":"Deciphering prognostic markers in gastric signet ring cell carcinoma: Human epidermal growth factor receptor 2 and other key factors.","authors":"Noura Atef A Ebrahim, Moamen O Othman, Neveen S Tahoun, Rasha A Salama, Aya Arafat, Nancy H Amin","doi":"10.5306/wjco.v16.i8.107987","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastric signet ring cell carcinoma (SRCC) is a rare, aggressive subtype of gastric cancer characterized by poor prognosis and distinctive biological behavior. Despite advances in gastric cancer treatment, SRCC remains difficult to diagnose early and manage effectively due to its infiltrative pattern and molecular variability. Reliable prognostic markers are critical to guide clinical management.</p><p><strong>Aim: </strong>To investigate the prognostic factors, including human epidermal growth factor receptor 2 (HER2) expression, associated with survival outcomes in patients with gastric SRCC.</p><p><strong>Methods: </strong>A retrospective analysis of 100 cases diagnosed between 2015 and 2019 was conducted, assessing demographic, clinical, and pathological data. HER2 expression was analyzed using immunohistochemistry, and survival outcomes, including overall survival and disease-free survival, were examined.</p><p><strong>Results: </strong>With a median follow-up of 43 months, the median patient age was 50 years, and males exhibited a higher mortality rate (<i>P</i> = 0.0107). Elevated serum carbohydrate antigen 19-9 and carcinoembryonic antigen levels were significantly associated with increased mortality (<i>P</i> = 0.00149 and <i>P</i> = 0.00163, respectively). Advanced tumor-node-metastasis stage and lymphovascular invasion were strong predictors of poor outcomes (<i>P</i> < 0.001 and <i>P</i> = 0.019). HER2 positivity correlated with higher mortality (<i>P</i> = 0.00882) but was not significantly linked to recurrence (<i>P</i> = 0.53). Surgical treatment significantly improved survival compared with non-surgical approaches (<i>P</i> = 0.0226).</p><p><strong>Conclusion: </strong>These findings highlight the aggressive nature of SRCC with advanced disease stage, elevated tumor markers, and lymphovascular invasion contributing to poor outcomes. HER2 expression, though infrequent, may indicate worse prognosis, reinforcing the role of surgical intervention in survival improvement.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107987"},"PeriodicalIF":3.2000,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400182/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i8.107987","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gastric signet ring cell carcinoma (SRCC) is a rare, aggressive subtype of gastric cancer characterized by poor prognosis and distinctive biological behavior. Despite advances in gastric cancer treatment, SRCC remains difficult to diagnose early and manage effectively due to its infiltrative pattern and molecular variability. Reliable prognostic markers are critical to guide clinical management.
Aim: To investigate the prognostic factors, including human epidermal growth factor receptor 2 (HER2) expression, associated with survival outcomes in patients with gastric SRCC.
Methods: A retrospective analysis of 100 cases diagnosed between 2015 and 2019 was conducted, assessing demographic, clinical, and pathological data. HER2 expression was analyzed using immunohistochemistry, and survival outcomes, including overall survival and disease-free survival, were examined.
Results: With a median follow-up of 43 months, the median patient age was 50 years, and males exhibited a higher mortality rate (P = 0.0107). Elevated serum carbohydrate antigen 19-9 and carcinoembryonic antigen levels were significantly associated with increased mortality (P = 0.00149 and P = 0.00163, respectively). Advanced tumor-node-metastasis stage and lymphovascular invasion were strong predictors of poor outcomes (P < 0.001 and P = 0.019). HER2 positivity correlated with higher mortality (P = 0.00882) but was not significantly linked to recurrence (P = 0.53). Surgical treatment significantly improved survival compared with non-surgical approaches (P = 0.0226).
Conclusion: These findings highlight the aggressive nature of SRCC with advanced disease stage, elevated tumor markers, and lymphovascular invasion contributing to poor outcomes. HER2 expression, though infrequent, may indicate worse prognosis, reinforcing the role of surgical intervention in survival improvement.
期刊介绍：
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
